Alexion Pharmaceuticals Is Still A Buy, Despite Rx Kanuma's Review-Date Delay
September 04, 2015 at 15:27 PM EDT
In a report issued Friday, Brean Capital analyst Jonathan Aschoff looks into Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and, after ...